Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Subscribe To Our Newsletter & Stay Updated
